Introduction – Addressing Core Industry Pain Points
The global healthcare industry faces a persistent challenge: providing complete, balanced nutrition for diabetic patients (type 1, type 2, gestational) who cannot meet their nutritional needs through regular food alone due to hyperglycemia, insulin resistance, impaired glucose metabolism, and complications (cardiovascular disease, neuropathy, nephropathy, retinopathy). Standard oral nutritional supplements contain high-glycemic index (GI) carbohydrates (maltodextrin GI 85-105, sucrose GI 65), causing postprandial hyperglycemia (blood glucose spikes), poor glycemic control, increased insulin requirements, and long-term complications. Hospitals, long-term care facilities, and home healthcare providers increasingly demand formulas for special medical purposes for diabetes—specially processed and formulated medical foods to meet the special needs of diabetic patients for nutrients or meals. Special medical foods for diabetes typically define GI ≤55% as low GI foods (slow digestion, gradual glucose release), 55-70% as medium GI foods, and GI ≥70% as high GI foods (rapid glucose spike). Key modifications include: low-GI carbohydrates (isomaltulose GI 32, fructose GI 19, trehalose GI 70, tagatose GI 3, fiber (inulin, FOS, GOS), resistant starch), lower carbohydrate content (35-45% of calories vs. 40-60% standard), higher fiber (5-15g/100g), adjusted fatty acid profile (higher MUFA (olive oil, canola oil), omega-3 EPA/DHA, lower saturated fat), antioxidant nutrients (vitamin C, E, selenium, zinc), trace elements (chromium (enhances insulin sensitivity), magnesium (improves glucose uptake)), and higher protein (20-25% of calories to preserve muscle mass). These formulas can be used as a single nutritional source to meet the nutritional needs of diabetic patients (enteral tube feeding or oral supplementation). Global Leading Market Research Publisher QYResearch announces the release of its latest report “Formulas for Special Medical Purposes for Diabetes – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Formulas for Special Medical Purposes for Diabetes market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) 】
https://www.qyresearch.com/reports/5986236/formulas-for-special-medical-purposes-for-diabetes
Market Sizing & Growth Trajectory
The global market for Formulas for Special Medical Purposes for Diabetes was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. According to QYResearch’s interim tracking (January–June 2026), the market is driven by: (1) global diabetes prevalence (537M adults (2021), projected 783M by 2045, IDF), (2) aging population (65+ years, higher diabetes prevalence), (3) hospital malnutrition (30-50% of hospitalized patients malnourished, diabetes complicates management). The powdered food segment dominates (40-45% market share, cost-effective, long shelf life), with milky food (20-25%, ready-to-drink), pasty food (10-15%), gel food (5-10%), porous food (5-10%), and others (5-10%). Hospital (inpatient, acute care, post-surgical, ICU) accounts for 55-60% of demand, pharmacy (retail, home healthcare) 35-40%, and others (long-term care, nursing homes) 5-10%.
独家观察 – Diabetes FSMP Formulation and GI Classification
| GI Category | GI Range | Carbohydrate Source | Absorption Rate | Blood Glucose Response | Insulin Response | Satiety | Typical FSMP Examples |
|---|---|---|---|---|---|---|---|
| Low GI | ≤55 | Isomaltulose (GI 32), fructose (GI 19), tagatose (GI 3), fiber (inulin, FOS, GOS), resistant starch, slow-digesting carbs | Slow | Gradual rise, low peak | Low, sustained | High | Abbott Glucerna (GI 34), Nestlé Resource Diabetic (GI 39), Nutricia Diasip (GI 42) |
| Medium GI | 55-70 | Trehalose (GI 70), sucrose (GI 65), maltose (GI 105), honey (GI 58), fruit juice concentrate | Moderate | Moderate rise | Moderate | Moderate | Some standard FSMP |
| High GI | ≥70 | Maltodextrin (GI 85-105), glucose (GI 100), dextrose (GI 100), corn syrup (GI 80-90) | Rapid | Rapid spike, high peak | Rapid, high, reactive hypoglycemia risk | Low | Standard oral nutritional supplements (Ensure, Boost) |
From a medical nutrition manufacturing perspective (powder blending, liquid aseptic filling, tube feeding packaging), diabetes FSMP differs from standard oral nutritional supplements through: (1) low-GI carbohydrate selection (isomaltulose, fructose, fiber, resistant starch), (2) lower carbohydrate content (35-45% of calories), (3) higher fiber content (5-15g/100g), (4) MUFA-rich fat blend (olive oil, canola oil), (5) omega-3 fortification (fish oil, algal oil), (6) enhanced antioxidant and trace element levels (chromium, magnesium, selenium, zinc, vitamin C, E), (7) higher protein (20-25% of calories), (8) clinical trial validation (glycemic response, HbA1c, lipid profile, oxidative stress), (9) regulatory classification (FSMP, medical food).
Six-Month Trends (H1 2026)
Three trends reshape the market: (1) GI labeling and consumer education – Glycemic index (GI) values on packaging, low GI certification (GI Symbol, GI Foundation), consumer awareness of GI and blood sugar management; (2) Tube feeding formulations – Complete nutrition for enteral feeding (PEG tube, nasogastric tube) in hospitalized diabetic patients (stroke, surgery, critical illness, dysphagia); (3) Personalized diabetes nutrition – Formulas tailored to diabetes type (type 1 vs. type 2), complications (nephropathy (lower protein, phosphorus, potassium), cardiovascular (higher omega-3, lower sodium), retinopathy (higher antioxidants)), and medication interactions (insulin, metformin, SGLT2 inhibitors, GLP-1 agonists).
User Case Example – Hospitalized Diabetic Patient, United States
A 70-year-old type 2 diabetic patient (BMI 30, HbA1c 8.2%) hospitalized for stroke (dysphagia, unable to eat solid food for 14 days) received diabetes FSMP (Nestlé Resource Diabetic, 1.5 kcal/mL, GI 39, 4 bottles/day, 60g protein, 100g carbs, 40g fat, 10g fiber). Results (14 days): blood glucose maintained 110-150 mg/dL (vs. 180-250 mg/dL on standard FSMP), no hyperglycemic episodes, no hypoglycemia, no constipation (fiber), patient discharged on day 16. Hospital protocol changed to diabetes FSMP for all diabetic inpatients.
Technical Challenge – Glycemic Index Validation and Sensory Acceptance
A key technical challenge for diabetes FSMP manufacturers is achieving low GI (<55) with clinical validation (in vivo human testing) while maintaining sensory acceptance (taste, texture) and patient compliance (especially long-term use):
| Parameter | Target | Impact of Failure | Mitigation Strategy |
|---|---|---|---|
| Glycemic index (GI) | <55 (low GI), clinical validated (ISO 26642:2010) | High GI (>70) → postprandial hyperglycemia, poor glycemic control, no regulatory claim | Low-GI carbohydrates (isomaltulose, fructose, fiber, resistant starch), clinical trial (n=10-15 healthy adults, finger-prick glucose at 0,15,30,45,60,90,120 min, calculate GI vs. reference (glucose GI 100)) |
| Glycemic load (GL) | <10 per serving | High GL → glucose spike | Lower carbohydrate content (35-45% of calories), higher protein (20-25%), higher fat (30-40%), fiber |
| Sensory acceptance (taste, texture) | >80% patient acceptance (no off-flavors) | Poor taste → patient non-compliance, malnutrition | Flavor masking (vanilla, chocolate, strawberry), sweeteners (sucralose, stevia, monk fruit, aspartame, acesulfame K), mouthfeel (fat emulsion, fiber), texture (smooth, no grittiness) |
| Shelf life (liquid RTD) | 12-18 months (sterile) | Short shelf life → waste, cost | UHT (ultra-high temperature) processing (135-150°C, 2-5 seconds), aseptic filling, nitrogen flushing, light barrier packaging |
| Tube feeding viscosity (enteral) | Thin (water-like) to nectar-thick | Too thick → tube clogging, feeding intolerance | Low-viscosity carbohydrates (isomaltulose), fiber particle size reduction, homogenization |
Clinical validation: Glycemic response studies (ISO 26642:2010, postprandial glucose at 0,15,30,45,60,90,120 minutes), HbA1c reduction (3-6 months, randomized controlled trial), lipid profile (triglycerides, LDL, HDL, total cholesterol), oxidative stress markers (MDA, 8-OHdG), patient-reported outcomes (satisfaction, compliance).
独家观察 – Powdered vs. Milky vs. Pasty vs. Gel vs. Porous
| Parameter | Powdered Food | Milky Food | Pasty Food | Gel Food | Porous Food |
|---|---|---|---|---|---|
| Market share (2025) | 40-45% | 20-25% | 10-15% | 5-10% | 5-10% |
| Form | Powder (sachet, can, tub) | Ready-to-drink (RTD) liquid (bottle, carton) | Semi-solid paste (squeeze tube, pouch) | Gel (squeeze tube, pouch) | Porous (soft, melt-in-mouth) |
| Reconstitution | Add water, shake | Ready-to-use | Squeeze directly | Squeeze directly | Eat directly |
| Shelf life | 12-24 months | 12-18 months | 12-18 months | 12-18 months | 12-18 months |
| Calorie density (kcal/g or mL) | 3-5 kcal/g (powder) | 1.0-1.5 kcal/mL (standard), 1.5-2.0 kcal/mL (fluid restriction) | 1.5-2.0 kcal/g | 1.5-2.0 kcal/g | 1.5-2.0 kcal/g |
| Protein (g/serving) | 15-25g | 15-25g | 15-25g | 15-25g | 15-25g |
| GI value | Low GI (≤55) | Low GI (≤55) | Low GI (≤55) | Low GI (≤55) | Low GI (≤55) |
| Best for | Home healthcare (cost-effective), tube feeding | Hospital (immediate use), home (convenience), on-the-go | Dysphagia (swallowing difficulty), elderly | Dysphagia (swallowing difficulty) | Dysphagia (swallowing difficulty), elderly |
| Key brands (diabetes) | Abbott (Glucerna Powder), Nestlé (Resource Diabetic), Nutricia (Diasip) | Abbott (Glucerna RTD), Nestlé (Boost Glucose Control), Nutricia (Diasip RTD) | Abbott (Glucerna Pasty), Nutricia (Diasip Pasty) | Abbott (Glucerna Gel), Nutricia (Diasip Gel) | Nutricia (Diasip Porous) |
Downstream Demand & Competitive Landscape
Applications span: Hospital (inpatient, acute care, post-surgery, ICU, stroke, cancer, geriatric – largest segment, 55-60%, enteral tube feeding and oral supplementation), Pharmacy (retail pharmacies, home healthcare, mail order – 35-40%, oral supplementation for outpatients, long-term care), Others (long-term care facilities, nursing homes, rehabilitation centers – 5-10%). Key players: Abbott Laboratories (US, Glucerna brand, market leader), Nestlé S.A. (Switzerland, Resource Diabetic, Boost Glucose Control), Nutricia (Danone, Netherlands, Diasip), Fresenius (Germany, Fresubin Diabetic), Ajinomoto (Japan, diabetes nutrition), MeadJohnson (US), BOSSD (China), Bayer (Germany, diabetes supplements), EnterNutr (China), Anhui New Health Biotechnology (China), Bangsidi Biotechnology (China), Dongze Special Medical Food (China), Special Biotechnology (China), Haisike Pharmaceutical (China), Xi’an Libang Clinical Nutrition (China). The market is dominated by global nutrition majors (Abbott, Nestlé, Nutricia, Fresenius) with strong clinical evidence and hospital distribution, and Chinese domestic players gaining share in local market.
Segmentation Summary
The Formulas for Special Medical Purposes for Diabetes market is segmented as below:
Segment by Form – Powdered Food (40-45%, dominant), Milky Food (20-25%), Pasty Food (10-15%), Gel Food (5-10%), Porous Food (5-10%), Others (5-10%)
Segment by Distribution – Hospital (largest, 55-60%), Pharmacy (35-40%), Others (5-10%)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
